JP2012509860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509860A5 JP2012509860A5 JP2011536892A JP2011536892A JP2012509860A5 JP 2012509860 A5 JP2012509860 A5 JP 2012509860A5 JP 2011536892 A JP2011536892 A JP 2011536892A JP 2011536892 A JP2011536892 A JP 2011536892A JP 2012509860 A5 JP2012509860 A5 JP 2012509860A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- stereoisomers
- disorders
- oxide
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- XOZGEXKQMVAILQ-UHFFFAOYSA-N 3-phenylazetidine Chemical class C1NCC1C1=CC=CC=C1 XOZGEXKQMVAILQ-UHFFFAOYSA-N 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 150000001539 azetidines Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000000642 iatrogenic effect Effects 0.000 claims 3
- -1 3,4-difluorophenyl Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- IIMJENATWISUEQ-UHFFFAOYSA-N 3-(2,3-difluorophenyl)-1-ethyl-1-oxidoazetidin-1-ium-3-ol Chemical compound C1[N+](CC)([O-])CC1(O)C1=CC=CC(F)=C1F IIMJENATWISUEQ-UHFFFAOYSA-N 0.000 claims 1
- KCALIDHAVNYABJ-UHFFFAOYSA-N 3-(2,3-difluorophenyl)-1-ethyl-3-methoxyazetidine Chemical compound C1N(CC)CC1(OC)C1=CC=CC(F)=C1F KCALIDHAVNYABJ-UHFFFAOYSA-N 0.000 claims 1
- MGUIZZKQEHAKCI-UHFFFAOYSA-N 3-(2,3-difluorophenyl)-1-ethylazetidin-3-ol Chemical compound C1N(CC)CC1(O)C1=CC=CC(F)=C1F MGUIZZKQEHAKCI-UHFFFAOYSA-N 0.000 claims 1
- CWKGAUCSNBQSRW-UHFFFAOYSA-N 3-(2,3-difluorophenyl)-3-methoxyazetidine Chemical compound C=1C=CC(F)=C(F)C=1C1(OC)CNC1 CWKGAUCSNBQSRW-UHFFFAOYSA-N 0.000 claims 1
- JOMARVLVCHGVNH-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-1-ethylazetidin-3-ol Chemical compound C1N(CC)CC1(O)C1=CC=C(F)C(F)=C1 JOMARVLVCHGVNH-UHFFFAOYSA-N 0.000 claims 1
- NFRYGGMWFYDWAI-UHFFFAOYSA-N 3-(3,5-difluorophenyl)-1-ethylazetidin-3-ol Chemical compound C1N(CC)CC1(O)C1=CC(F)=CC(F)=C1 NFRYGGMWFYDWAI-UHFFFAOYSA-N 0.000 claims 1
- WTURPIIUMVVBNR-UHFFFAOYSA-N 3-(3-chloro-2-fluorophenyl)-1-ethylazetidin-3-ol Chemical compound C1N(CC)CC1(O)C1=CC=CC(Cl)=C1F WTURPIIUMVVBNR-UHFFFAOYSA-N 0.000 claims 1
- YJVAEBCJEVBOTP-UHFFFAOYSA-N 3-(3-chloro-5-fluorophenyl)-1-ethylazetidin-3-ol Chemical compound C1N(CC)CC1(O)C1=CC(F)=CC(Cl)=C1 YJVAEBCJEVBOTP-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 150000003943 catecholamines Chemical class 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000013843 drug-induced mental disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801656 | 2008-11-24 | ||
| DKPA200801656 | 2008-11-24 | ||
| US11781808P | 2008-11-25 | 2008-11-25 | |
| US61/117,818 | 2008-11-25 | ||
| PCT/EP2009/065675 WO2010058017A1 (en) | 2008-11-24 | 2009-11-24 | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509860A JP2012509860A (ja) | 2012-04-26 |
| JP2012509860A5 true JP2012509860A5 (enExample) | 2013-01-17 |
| JP5621087B2 JP5621087B2 (ja) | 2014-11-05 |
Family
ID=41649970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536892A Expired - Fee Related JP5621087B2 (ja) | 2008-11-24 | 2009-11-24 | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8586572B2 (enExample) |
| EP (1) | EP2367785B1 (enExample) |
| JP (1) | JP5621087B2 (enExample) |
| CN (1) | CN102224135A (enExample) |
| AU (1) | AU2009317155A1 (enExample) |
| CA (1) | CA2744307A1 (enExample) |
| MX (1) | MX2011005034A (enExample) |
| WO (1) | WO2010058017A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010058018A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| CN107646031B (zh) * | 2015-05-20 | 2020-11-17 | 综合研究实验室瑞典股份公司 | 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物 |
| FI3541784T3 (fi) | 2016-11-18 | 2023-10-02 | Integrative Res Laboratories Sweden Ab | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3668196A (en) * | 1965-10-22 | 1972-06-06 | Lilly Co Eli | 3-azetidinols |
| US3481920A (en) * | 1965-10-22 | 1969-12-02 | Lilly Co Eli | Azetidinones |
| US3822252A (en) | 1968-06-28 | 1974-07-02 | Schering Corp | 3-azetidinols |
| CH524598A (de) * | 1968-06-28 | 1972-06-30 | Scherico Ltd | Verfahren zur Herstellung neuer Azetidinderivate |
| GB1236078A (en) * | 1968-07-04 | 1971-06-16 | Beecham Group Ltd | Substituted azetidinols |
| US3494964A (en) | 1969-01-13 | 1970-02-10 | Lilly Co Eli | Alpha-halo-alpha-amino ketones |
| PT1049670E (pt) * | 1998-01-23 | 2002-12-31 | Vernalis Res Ltd | Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc |
| GB9917384D0 (en) * | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-III |
| US20050143372A1 (en) | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2005026153A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinazoline-2, 4-diones as antibacterial agents |
| WO2005026146A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Azetidinyl quinolones as antibacterial agents |
| CN1902169A (zh) * | 2003-11-10 | 2007-01-24 | 迈克罗比亚公司 | 4－联芳基－1－苯基氮杂环丁烷－2－酮 |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2611216A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | 3-phenylazetidine derivatives as dopamine agonists |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101808987A (zh) | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| MX2009012716A (es) | 2007-06-05 | 2009-12-14 | Nsab Af Neurosearch Sweden Ab | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. |
| WO2010058018A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| US20110257148A1 (en) | 2008-11-24 | 2011-10-20 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
-
2009
- 2009-11-24 US US13/130,384 patent/US8586572B2/en not_active Expired - Fee Related
- 2009-11-24 WO PCT/EP2009/065675 patent/WO2010058017A1/en not_active Ceased
- 2009-11-24 AU AU2009317155A patent/AU2009317155A1/en not_active Abandoned
- 2009-11-24 JP JP2011536892A patent/JP5621087B2/ja not_active Expired - Fee Related
- 2009-11-24 CA CA2744307A patent/CA2744307A1/en not_active Abandoned
- 2009-11-24 CN CN2009801464443A patent/CN102224135A/zh active Pending
- 2009-11-24 EP EP09756501.4A patent/EP2367785B1/en not_active Not-in-force
- 2009-11-24 MX MX2011005034A patent/MX2011005034A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008259841B2 (en) | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| NZ602754A (en) | Substituted 1,3-benzothiazepines useful in treating metabolic disorders | |
| RU2018130727A (ru) | Органические соединения | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP2013512926A5 (enExample) | ||
| MX2010004614A (es) | Composiciones para tratamiento del mal de parkinson. | |
| JP2010529081A5 (enExample) | ||
| BRPI0905849A2 (pt) | Composto, composição farmacêutica e método | |
| EA201071083A1 (ru) | Арилсульфонилпиразолинкарбоксамидиновые производные в качестве антагонистов 5-нт | |
| JP2014518552A5 (enExample) | ||
| JP2011518858A5 (enExample) | ||
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| RU2013147917A (ru) | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии | |
| NZ611323A (en) | Cyclopropyl amine derivatives as histamin h3 receptor modulators | |
| JP2012509860A5 (enExample) | ||
| RU2011120817A (ru) | Произволные 3-фенил-3-метоксипирролидина в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| JP2009511525A5 (enExample) | ||
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| JPWO2019183341A5 (enExample) | ||
| JP2011503233A5 (enExample) | ||
| MX2009007405A (es) | Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina. | |
| FI3625213T3 (fi) | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt | |
| JPWO2020132474A5 (enExample) | ||
| JP2019535715A5 (enExample) |